Choroideremia (CHM; OMIM #303100) is an X-linked retinal dystrophy that leads to the degeneration of the choriocapillaris, the retinal pigment epithelium, and the photoreceptors of the eye.
1 It is caused by loss-of-function mutations in the
CHM gene and presumably amenable to CHM gene replacement therapy.
2
Given its small size, the
CHM gene (1.9 kb) can be easily accommodated within an adeno-associated virus 2 vector and delivered to the photoreceptors and retinal pigment epithelium by subretinal injection.
3 During the past decade, several groups have reported the outcomes of clinical trials of CHM with adeno-associated virus 2 using a variety of measures.
3–6 Investigators seek accurate outcome measures to evaluate the effect of gene therapy on the outer retinal structures in patients with CHM, in particular the photoreceptors and retinal pigment epithelium. Among different imaging models, spectral domain-optical coherence tomography (SD-OCT) is considered to be a powerful tool to visualize the outer retinal structures.
7
Some natural history studies have used either SD-OCT–derived central foveal thickness, subfoveal choroidal thickness, or preserved choriocapillaris to monitor the progression of CHM disease.
8–10 The second hyper-reflective band of the retinal OCT, termed the ellipsoid zone (EZ), has been associated with the photoreceptor inner segment ellipsoid.
11 The preserved horizontal EZ length has been used to estimate the remaining photoreceptors in inherited retinal dystrophies such as retinitis pigmentosa.
12 In a previous adeno-associated virus 2–mediated CHM gene therapy trial, our site used the EZ length across the macula as an estimate of preserved photoreceptor structure.
4 However, the retinal atrophy in CHM typically has a scalloped margin with irregular retinal islands.
13 A measurement of the preserved en face EZ area would be ideal and could provide a more accurate estimate of the preserved photoreceptors. An accurate measure of preserved en face EZ area has the potential to be used as a marker to monitor disease progression as well as to evaluate the efficacy of experimental therapies. In this study, we used SD-OCT volume scans from patients with CHM to create en face EZ maps. We explore the options for quantifying photoreceptor structure and provide outcome measurements for future clinical trials. We also evaluate the relationship between the EZ and the preserved fundus autofluorescence (FAF) area.